```html

Quasi‑latent Tuberculosis Infection (QLTBI)

Overview

Quasi‑latent tuberculosis infection (QLTBI) is a recently defined spectrum of Mycobacterium tuberculosis (M.tb) infection that sits between classic latent TB infection (LTBI) and active disease. Individuals with QLTBI harbor viable bacilli that are not fully dormant; they produce low‑level immune‑mediated inflammation and may intermittently shed bacteria, yet they typically do not display the classic clinical picture of active pulmonary TB.

• Who it affects: Primarily adults who have previously been exposed to TB, especially those with immunomodulating conditions (e.g., HIV, diabetes, anti‑TNF therapy) or a history of recent infection.
• Prevalence: Exact global numbers are still emerging because QLTBI is identified by a combination of biomarkers, imaging, and microbiologic assays rather than a single test. Modeling studies suggest that up to 10‑15 % of people with a positive interferon‑γ release assay (IGRA) may actually have QLTBI rather than strictly latent infection [1]. In high‑burden countries, this could translate to several hundred thousand individuals.

Understanding QLTBI is important because these patients can progress to active disease faster than classic LTBI and may contribute to community transmission, especially in congregate settings.

Symptoms

Most people with QLTBI are asymptomatic or have very mild, nonspecific complaints. When symptoms do occur, they are often intermittent and may be mistaken for other common illnesses.

Typical symptom list

• Low‑grade fever – often < 38 °C (100.4 °F) and lasting a few days.
• Night sweats – usually mild, not drenching.
• Fatigue & malaise – persistent tiredness not explained by activity level.
• Occasional cough – dry or minimally productive; rarely associated with wheeze.
• Weight loss – usually <5 % of body weight over months.
• Chest discomfort – vague pressure or mild pleuritic pain.
• Low‑level sputum positivity – detectable by molecular assays (e.g., Xpert MTB/RIF) but not by routine smear microscopy.

Because these signs overlap with many other conditions, a high index of suspicion and targeted testing are essential.

Causes and Risk Factors

What causes QLTBI?

QLTBI arises when M.tb bacilli survive in a state of “partial dormancy.” This can be due to:

• Incomplete clearance after primary infection.
• Host immune responses that are sufficient to prevent overt disease but not strong enough to eradicate all organisms.
• Genetic variations in M.tb that favor a low‑metabolic state.
• Environmental stresses (e.g., hypoxia, nutrient limitation) within granulomas that push bacilli into a quasi‑latent phenotype.

Key risk factors

• Immunosuppression: HIV infection (especially CD4 <200 cells/µL), solid organ transplantation, anti‑TNFα agents, corticosteroids ≥15 mg/day for >1 month.
• Chronic diseases: Diabetes mellitus (risk ↑2‑3×), chronic kidney disease, silicosis.
• Recent exposure: Living with a person who has active pulmonary TB within the last 2 years.
• Age: Adults >45 years have a higher likelihood of progressing from LTBI to QLTBI.
• Socio‑economic factors: Overcrowded housing, poor ventilation, malnutrition.
• Previous TB treatment: Incomplete or irregular therapy can leave persisting organisms that become quasi‑latent.

Diagnosis

No single test definitively confirms QLTBI. Diagnosis relies on a composite of clinical, radiologic, immunologic, and microbiologic data.

Step‑by‑step diagnostic approach

1. Screening tests – IGRA (e.g., QuantiFERON‑TB Gold) or Tuberculin Skin Test (TST) to establish M.tb sensitization.
2. Risk assessment – Detailed exposure history, comorbidities, and immunologic status.
3. Chest imaging –
   • Chest X‑ray: May show subtle fibrotic scars, calcified nodules, or “tree‑in‑bud” patterns.
   • High‑resolution CT (HRCT): More sensitive; can reveal small (<5 mm) nodules, focal mediastinal lymphadenopathy, or early cavitation not seen on plain film.
4. Advanced biomarkers –
   • RNA‑based signatures: Host‑transcriptomic assays (e.g., the 3‑gene “TB‑risk” signature) differentiate QLTBI from true latency with >80 % sensitivity [2].
   • Quantiferon‑TB Gold Plus (QFT‑Plus) with antigen‑specific IFN‑γ measurement: Higher IFN‑γ responses in the “TB2” tube suggest recent or active infection.
5. Sputum analysis (when cough is present) –
   • GeneXpert MTB/RIF Ultra: can detect ≤10 CFU/mL, useful for low‑level bacillary shedding.
   • Liquid culture (MGIT) – gold standard for viability but may be negative in QLTBI.
6. Exclusion of active disease – Ensure there are no radiographic features of progressive cavitation, extensive infiltrates, or systemic signs (e.g., high fever, weight loss >10 %).

When the above criteria align—positive IGRA, compatible imaging, low‑level molecular detection, and lack of overt disease—clinicians may label the condition as QLTBI.

Treatment Options

The therapeutic goal is to eradicate the residual bacilli, prevent progression to active TB, and reduce the low but measurable transmission risk.

First‑line regimens (recommended by WHO 2023 and CDC 2024)

• 3HP: Isoniazid 15 mg/kg + Rifapentine 15 mg/kg, once weekly for 12 weeks (directly observed therapy recommended).
• 4R: Rifampin 10 mg/kg daily for 4 months – an alternative for patients with contraindications to isoniazid.

Alternative or adjunctive regimens

• 9H: Isoniazid daily for 9 months – used when weekly dosing is not feasible.
• 6–9 month Rifampin‑plus‑Isoniazid (HR) combo: Considered for patients with HIV or diabetes.
• Fluoroquinolone‑containing regimens: Levofloxacin 750 mg daily for 4 months in cases of isoniazid resistance.

Management of drug‑resistant QLTBI

If molecular testing identifies rifampin or isoniazid resistance, a regimen similar to that for multidrug‑resistant (MDR) TB contacts is employed—typically a combination of fluoroquinolones, bedaquiline, and linezolid for 6–12 months, under specialist supervision.

Lifestyle & supportive measures

• Optimal nutrition (protein ≥ 1.2 g/kg/day, vitamin D 800–1000 IU/day).
• Smoking cessation – reduces risk of progression by ~50 %.
• Regular physical activity (≥150 min moderate‑intensity/week).
• Management of comorbidities (tight glycemic control, antiretroviral therapy adherence).

Living with Quasi‑latent Tuberculosis Infection

Living with QLTBI is generally compatible with normal daily activities, but some practical steps can support treatment adherence and overall health.

Daily management tips

1. Medication adherence: Use a pill organizer or set alarms; consider weekly directly observed therapy (DOT) for 3HP.
2. Monitor for side effects:
   • Isoniazid – check liver function tests (LFTs) at baseline and every 2–3 months.
   • Rifapentine/Rifampin – watch for orange discoloration of body fluids, drug interactions (e.g., with anticoagulants, oral contraceptives).
3. Follow‑up schedule: Clinic visits at 2 weeks, 1 month, then monthly until completion.
4. Vaccinations: Stay up‑to‑date on influenza and COVID‑19 vaccines; BCG is not indicated in adults with QLTBI.
5. Travel considerations: Avoid high‑risk settings (prisons, shelters) during the first few months of therapy.

Psychosocial support

Stigma can accompany any TB‑related diagnosis. Encourage patients to join support groups, and provide educational materials to family members to reduce fear and misinformation.

Prevention

Because QLTBI originates from prior exposure, primary prevention focuses on reducing initial infection and on early identification of contacts.

• Environmental controls: Adequate ventilation (≥12 air changes per hour) in homes, workplaces, and congregate settings.
• Contact tracing: Rapid screening of household and close contacts of active TB cases; treat LTBI or QLTBI promptly.
• Infection control in healthcare: Use of N95 respirators, negative‑pressure rooms for suspected active TB patients.
• Vaccination research: Novel TB vaccines (e.g., MTBVAC) are under trial and may eventually lower the risk of quasi‑latent infection.

Complications

If QLTBI is left untreated, several adverse outcomes may occur:

• Progression to active TB: Estimated annual risk 0.5‑1 %—higher than classic LTBI (≈0.1 %).
• Transmission: Low‑level bacillary shedding can seed others, especially in closed environments.
• Liver toxicity: From prolonged isoniazid or rifampin use, potentially leading to acute hepatitis.
• Drug‑resistance development: Incomplete treatment may select for resistant strains.
• Extrapulmonary disease: Rarely, bacilli can disseminate to lymph nodes, bone, or the central nervous system.

When to Seek Emergency Care

---

References

1. World Health Organization. Global Tuberculosis Report 2023. WHO; 2023.
2. Zak, D. et al. “A blood RNA signature for tuberculosis disease risk.” Nature Medicine 2022;28:1559‑1567.
3. Centers for Disease Control and Prevention. “Treatment of Latent Tuberculosis Infection.” 2024. cdc.gov/tb/treatment/latent
4. Mayo Clinic. “Tuberculosis (TB).” Updated 2024. mayoclinic.org
5. Cleveland Clinic. “Latent TB infection – Management and treatment.” 2023. clevelandclinic.org

```